| Osteoporosis Drug Strengthens Bones In Men With Prostate Cancer -
25-03-2007, 01:07 AM
A small trial of 112 men with prostate cancer who were receiving androgen deprivation therapy found that men assigned to take an oral dose of alendronate had less bone loss or bone turnover and increased bone mineral density of the spine and hip at the end of one year than men assigned to a placebo
Androgen deprivation therapy involves reducing hormones such as testosterone that encourage cancer growth. Alendronate, a bisphosphonate, is best known as an anti-osteoporosis drug.
The groups did not differ significantly in adverse side effects. The study was not designed to show whether alendronate reduces fractures. | 
Linear Mode
